Clinical Trial Update: Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the PET tracer [18F] PBR111 as a marker of brain inflammation in Alzheimer's disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• [18F]PBR111 (PBR111 fluorine-18 radioligand for translocator protein (TSPO))

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Alzheimer Disease | Phase 1 | Status: COMPLETED